e-Drug3D

519

cas 13311-84-7

CLASS

ANTINEOPLASTIC
ANTIANDROGENIC

ROUTE (list)

ORAL

PK parameters

F 100 PERCENT
Tmax 1.3 HOUR
Cmax 282.6 NANOMOLAR
PPB 95 PERCENT
t1/2 7.8 HOUR

MW 276.22
NB_atoms 19
XLogP 0
PSA 62.758
NB_HD 1
NB_HA 4
fsp3 0.36
Lipinski(0=no;1=yes) 1

FDA
NDA 018554 (label) INN (FLUTAMIDE) EULEXIN (SCHERING) APPROVAL= AP YEAR= 1989 DISCONTINUED
NDA 075298 (pdf not found) INN (FLUTAMIDE) FLUTAMIDE (WAYLIS THERAP) APPROVAL= AP YEAR= 2001
NDA 075780 (pdf not found) INN (FLUTAMIDE) FLUTAMIDE (CIPLA) APPROVAL= AP YEAR= 2001 DISCONTINUED
NDA 075818 (pdf not found) INN (FLUTAMIDE) FLUTAMIDE (CHARTWELL RX) APPROVAL= AP YEAR= 2001 DISCONTINUED
NDA 075820 (pdf not found) INN (FLUTAMIDE) FLUTAMIDE (ACTAVIS LABS FL INC) APPROVAL= AP YEAR= 2001 DISCONTINUED
NDA 076224 (pdf not found) INN (FLUTAMIDE) FLUTAMIDE (PHARMOBEDIENT) APPROVAL= AP YEAR= 2003 DISCONTINUED

e-Drug3D

1705

cas 52806-53-8

CLASS

ANTINEOPLASTIC
ANTIANDROGENIC

ROUTE (list)

-

PK parameters

Tmax 2 HOUR
Cmax 7.8 MICROMOLAR
PPB 93 PERCENT
t1/2 6 HOUR

TARGET ANDROGEN RECEPTOR

PDB
4OH6 (CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE)

Ligand code = HFT (link to the list of PDB complexes)

Download experimental 3D coordinates of HFT with added hydrogens

MW 292.22
NB_atoms 20
XLogP 2.32
PSA 83.228
NB_HD 2
NB_HA 5
fsp3 0.36
Lipinski(0=no;1=yes) 1

FDA
-